Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

The moments that last forever

What is the true value of health to our lives? And what contribution are we making at Fresenius? Watch our new animated image film!
Watch the image film
Growing up with parenteral nutrition

How two brave adventurers from Switzerland are exploring the world step-by-step.
Read the story
Saving lives – with and beyond dialysis

On the occasion of Fresenius Medical Care's 25th anniversary, CEO Rice Powell and Global Chief Medical Officer Franklin W. Maddux, MD, discuss ways to further improve the lives of kidney disease patients.
Read the story
Doubling up on a second chance

Twin brothers Kilian and Jamie both suffered from a heart weakness. Just three days apart, they each received a transplanted heart at Fresenius Helios.
Read the story

News

Brief News
Fresenius Helios acquires majority stake in U.S. fertility center

The Eugin Group, part of Fresenius Helios, acquires a majority stake in the Delaware Institute for Reproductive Medicine (DIRM), a renowned fertility center in the U.S. state of Delaware that has been established for 35 years. With this acquisition, Eugin further expands its existing network in the U.S. and expects to generate additional synergies and operational efficiencies. A number of key physicians will remain minority shareholders in DIRM. Both sides have agreed not to disclose financial details.

January 10, 2022Fresenius Helios

Brief News
Fresenius Kabi modernizes production facility in France

Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.

December 13, 2021Fresenius Kabi
Brief News
Fresenius again with top result in climate ranking

In this year's ranking, the non-profit organization CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

December 08, 2021Fresenius

Brief News
Fresenius Medical Care with top result in climate ranking

In this year's ranking, the non-profit organization CDP has confirmed Fresenius Medical Care' classification. The company was again listed in the second highest categories B in the area climate and B- in the area water. Fresenius Medical Care is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

December 08, 2021Fresenius Medical Care
Fresenius Medical Care announces changes to Management Board, reflecting the transformation to the company’s new operating model

December 01, 2021Fresenius Medical Care

Fresenius Medical Care’s new FX CorAL dialyzer combines clinical performance with hemocompatibility

November 29, 2021Fresenius Medical Care
Fresenius Helios acquires oncological center and ophthalmic clinic in Colombia

November 22, 2021Fresenius Helios

Brief News
Fresenius SE & Co. KGaA again included in Dow Jones Sustainability Index

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent based on the international investment company S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Cybersecurity, Data Protection and Human Rights. In the area of Partnerships towards sustainable healthcare, Fresenius was awarded the maximum score in the rating 2021.

November 16, 2021Fresenius
Brief News
Fresenius Medical Care included for 12th time in Dow Jones Sustainability Index

Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, has been recognized for the 12th time as a sustainability leader, with inclusion in the Dow Jones Sustainability Index. The DJSI Europe is composed of the top 20 percent of the largest 600 European companies listed in the S&P Global BMI, based on the international investment company S&P Global’s analysis of their economic, environmental and social performance. Fresenius Medical Care achieved improvements in most categories and was awarded maximum scores for partnerships toward sustainable healthcare, environmental reporting and social reporting. The company’s scores also rose significantly in the areas of risk management and customer relationship management.

November 16, 2021Fresenius Medical Care

Brief News
Fresenius Kabi enters collaboration to enhance controlled substance management in the U.S.

Fresenius Kabi and Omnicell, Inc are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Omnicell has designed new cassettes for its Controlled Substance Dispenser specifically for Fresenius Kabi Simplist® MicroVault® pre-filled syringes. The new cassettes provide customers with more flexibility and enhanced options for controlled substance management. The collaboration with Omnicell is an example of the continued investment Fresenius Kabi has made in its Simplist® portfolio. The investment has resulted in more Simplist® products for customers to choose from including those that offer radio frequency identification (RFID) technology.

November 10, 2021Fresenius Kabi
Fresenius improves FY/21 Group guidance for the second time after good Q3 results

November 02, 2021Fresenius

Fresenius Medical Care confirms outlook for 2021 while considering the continued negative impact of COVID-19

November 02, 2021Fresenius Medical Care
Fresenius Medical Care transforms its operating model, entering the next phase of its 2025 growth strategy

November 02, 2021Fresenius Medical Care

Fresenius Medical Care further enhances clinical care through continuous digital quality improvement

October 25, 2021Fresenius Medical Care
Brief News
Fresenius Kabi enters collaboration to enhance the supply of essential medicines for U.S. Patients

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

October 14, 2021Fresenius Kabi

Fresenius Medical Care donates 250,000 euros to UNICEF

October 04, 2021Fresenius Medical Care
Fresenius Medical Care publishes 2021 Global Annual Medical Report: Embracing the Complexity of Global Healthcare

September 23, 2021Fresenius Medical Care

Brief News
2022 DRG inflator for German hospitals set at 2.29%

The price increase for hospital services in Germany has been set at 2.29% for 2022. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 15, 2021Fresenius Helios
Fresenius Medical Care celebrates 25th anniversary

September 09, 2021Fresenius Medical Care

Brief News
Fresenius Helios publishes second sustainability report

Helios Germany has published its second sustainability report. The 60 pages report "Strong into the future" looks back on the complex challenges of the Corona year 2020 and shows in which areas the pandemic has driven developments for Germany’s largest private hospital operator. Helios Germany has defined four fields for its sustainability strategy: Patients, employees, the environment and compliance. Like the first report in 2019, it was drawn up based on the GRI standards of the Global Reporting Initiative and is now available in German on www.helios-gesundheit.de/nachhaltigkeit. An English version will be published soon.

September 08, 2021Fresenius Helios

Disclaimer All news

NEXT EVENT

February

22

February 22, 2022 | Bad Homburg v.d.H.

Press Conference Full Year Results 2021, Fresenius and Fresenius Medical Care

Import (ICS)

NEXT EVENT

Library

All Downloads

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us